Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred ...

The management of carotid-artery stenosis that has not caused recent symptoms — asymptomatic carotid stenosis — has been controversial. Clinical trials that began more than 30 years ago showed a small ...

This feature about a man hospitalized for uncomplicated diverticulitis who is found to have high blood pressure offers a case vignette accompanied by two essays, one supporting watchful waiting and ...

A 26-year-old woman was referred to the pulmonary hypertension clinic with a 6-month history of exertional dyspnea and hoarseness. Vocal-fold paralysis was seen on laryngoscopy (shown in a video).

Joshua Barocas is an associate professor of medicine at the University of Colorado Anschutz Medical Campus. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.

A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The FDA outlines a path to market entry for products where a randomized trial is no ...

To the Editor: The results of the C-POST trial, reported by Rischin and colleagues (August 21/28 issue), 1 highlight improvements in disease-free survival with adjuvant cemiplimab. As the authors ...

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...

The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and ...

We conducted an international, open-label, randomized, blinded-outcome-assessment trial involving 1284 patients who had undergone successful catheter ablation for atrial fibrillation at least 1 year ...